

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Comparative bioequivalence Study of the Eltrombopag 50 mg Tablets, Manufactured by Arang Daroo Darman Pharmaceutical Company by Innovative Company (Revolade)

Protocol summary

Study aim

Comparison Bioequivalence study of Eltrombopag 50 mg tablets produce by Daroo Darman Arang Pharmaceutical Company and Its the brand Product

Design

This study is a single-blind crossover study with two intervention groups of 12, randomized by the Rand function of SPSS software. The sample size is 24, randomly selected and randomly divided into two groups.

Settings and conduct

In this study, which will be conducted at the Tabriz Bioassay Drug Monitoring Laboratory, there are two intervention groups that have been randomized using the Rand function of SPSS software. The first and second groups will take the Iranian and brand-name drugs, respectively, without knowing it, and blood will be drawn at specific intervals. Since it is one-sided, this procedure will be repeated after a washout period and the equivalence of the drugs will be examined.

Participants/Inclusion and exclusion criteria

Inclusion criteria: General health (liver, heart, and kidney) Body mass index between 18 and 28) Informed consent Age between 18-60 years Exclusion criteria: Smoking History of cardiovascular disease Pregnancy Alcohol and drug addiction History of allergy to this drug

Intervention groups

In this study, there are two intervention groups, the first and second groups taking Iranian and branded drugs, respectively. After a cleansing period, this process is reversed and the equivalence of the drugs is examined based on blood concentrations taken at specific times.

Main outcome variables

Drug Concentration

General information

Reason for update

Acronym

None

IRCT registration information

IRCT registration number: **IRCT20231108059993N8**

Registration date: **2025-10-23, 1404/08/01**

Registration timing: **prospective**

Last update: **2025-10-23, 1404/08/01**

Update count: **0**

Registration date

2025-10-23, 1404/08/01

Registrant information

Name

Iran Ghanbarzadeh

Name of organization / entity

Alborz University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 41 3383 2649

Email address

s_ghanbarzadeh@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2025-11-05, 1404/08/14

Expected recruitment end date

2025-11-19, 1404/08/28

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative bioequivalence Study of the Eltrombopag 50 mg Tablets, Manufactured by Arang Daroo Darman Pharmaceutical Company by Innovative Company (Revolade)

Public title

Comparative bioequivalence study of the Eltrombopag 50 mg Tablets, Manufactured by Daroo Darman Arang Pharmaceutical Company

Purpose

Other

Inclusion/Exclusion criteria**Inclusion criteria:**

Must be in good general health (liver, heart, and kidneys). Body mass index should be in the range of 18-28. Informed consent must be obtained. Age must be between 18-60 years.

Exclusion criteria:

History of allergic or adverse reaction to eltrombopag or any similar product. Addiction to cigarettes, alcohol, or any type of drug. Volunteers with a history of chronic diseases such as high blood pressure or high blood lipids, etc. who have taken medication in the past two months.

Age

From **18 years** old to **60 years** old

Gender

Male

Phase

Bioequivalence

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

Individuals in the age group mentioned are invited to participate through an advertisement. Then, individuals are checked for health and healthy volunteers are identified. Each volunteer is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. Then, balls are randomly removed from the container. The first 12 people are considered as (sequence one: recipients of eltrombopag 50) and the second 12 people are considered as (sequence two: recipients of rovalipin 50). The participating volunteers are unaware of receiving the test drug or the brand drug.

Blinding (investigator's opinion)

Single blinded

Blinding description

This study is a single-blind (participant) clinical trial. Eltrombopag tablets are removed from their packaging by the investigator and placed in identical, coded containers. Volunteers are unaware of the type of drug they are taking in each series of the experiment.

Placebo

Not used

Assignment

Crossover

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of .Tabriz University of Medical Sciences

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences Daneshgah St. Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5167698354184

Approval date

2025-10-06, 1404/07/14

Ethics committee reference number

IR.TBZMED.REC.1404.526

Health conditions studied**1****Description of health condition studied**

Healthy volunteer

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

At specific intervals, the blood concentration of the drug is measured and compared in two series of blood draws, and it is determined whether the drugs are equivalent or not.

Timepoint

Drug concentrations are measured at time intervals of 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours after drug administration.

Method of measurement

Liquid chromatography with dual mass spectrometer
LC/MS/MS

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1 receives an Iranian drug and blood concentrations are obtained at specific time intervals. In the second series, this group receives the brand name drug.

Category

Other

2

Description

The intervention group receives 2 brand drugs and blood concentrations are obtained at specific intervals. In the second series, this group receives the Iranian drug. Finally, the results obtained from the two intervention groups are compared and it is determined whether they are equivalent or not.

Category

Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Payesh Daroo Zist Azma

Full name of responsible person

Saeed Ghanbarzadeh

Street address

No 10, Ave Mehrab, Ave Mirdamad

City

Tabriz

Province

East Azarbaijan

Postal code

5186733653

Phone

+98 41 3383 2649

Email

s_ghanbarzadeh@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Arang Daroo Darman

Full name of responsible person

Alireza Mahbobian

Street address

Sheikh bahaee, Molla sadra

City

Tehran

Province

Tehran

Postal code

5166934184

Phone

+98 41 3383 2649

Fax

Email

Info@Arangpharm.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Arang Daroo Darman

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Phayesh Daroo Zist Azma

Full name of responsible person

Saeed Ghanbarzadeh

Position

Ph.D of Pharmaceutics

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 10, Ave Mehrab, Ave Mirdamad

City

Tabriz

Province

East Azarbaijan

Postal code

5166934184

Phone

+98 41 3383 2649

Email

s_ghanbarzadeh@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arang Daroo Darman

Full name of responsible person

Saeed Ghanbarzadeh

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 10, Mehrab, Ave, Mirdalad Ave

City

Tabriz

Province

East Azarbaijan

Postal code

۱۹۹۳۶۷۴۸۵۵

Phone

+98 21 8806 4460

Email

s_ghanbarzadeh@yahoo.com

+98 41 3383 2649

Email

s_ghanbarzadeh@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Not applicable

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

None

When the data will become available and for how long

None

To whom data/document is available

None

Under which criteria data/document could be used

None

From where data/document is obtainable

None

What processes are involved for a request to access data/document

None

Comments

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Saeed Ghanbarzadeh

Position

Associated Proffesor

Latest degree

Ph.D.

Other areas of specialty/work

Pharmaceutics

Street address

No 10, Mehrab Ave, Mirdamad Ave

City

Tabriz

Province

East Azarbaijan

Postal code

5166934184

Phone